SEC Form 4 · accession 0001127602-18-035379
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theresa Heggie
Director
Period of report
Dec 3, 2018
Accepted (ET)
Dec 6, 2018 · 4:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF1 | $9.27 | Dec 3, 2018 | A | 30,000 | A | Dec 3, 2019 | Dec 3, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan.